Legend Biotech Corp
NASDAQ:LEGN
Legend Biotech Corp
NASDAQ:LEGN
Price:
18.13
USD
-1.25%
Market Closed
Market Cap:
$3.3B
Balance Sheet
Balance Sheet Decomposition
Legend Biotech Corp
Legend Biotech Corp
Balance Sheet Decomposition is not available for
Legend Biotech Corp
Legend Biotech Corp
Balance Sheet
Legend Biotech Corp
Legend Biotech Corp
Currency: USD
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
2
|
210
|
83
|
456
|
689
|
786
|
1 278
|
287
|
|
| Cash Equivalents |
2
|
210
|
83
|
456
|
689
|
786
|
1 278
|
287
|
|
| Short-Term Investments |
0
|
6
|
76
|
50
|
195
|
241
|
31
|
836
|
|
| Total Receivables |
228
|
26
|
30
|
83
|
58
|
46
|
157
|
125
|
|
| Accounts Receivables |
228
|
26
|
30
|
75
|
50
|
0
|
100
|
6
|
|
| Other Receivables |
0
|
0
|
0
|
8
|
8
|
45
|
57
|
119
|
|
| Inventory |
0
|
1
|
1
|
2
|
2
|
10
|
19
|
24
|
|
| Other Current Assets |
1
|
83
|
22
|
4
|
6
|
16
|
12
|
12
|
|
| Total Current Assets |
231
|
327
|
212
|
594
|
950
|
1 099
|
1 498
|
1 284
|
|
| PP&E Net |
3
|
32
|
73
|
112
|
141
|
161
|
189
|
201
|
|
| PP&E Gross |
3
|
32
|
0
|
112
|
141
|
161
|
189
|
201
|
|
| Accumulated Depreciation |
0
|
1
|
0
|
11
|
17
|
25
|
35
|
44
|
|
| Intangible Assets |
0
|
0
|
1
|
3
|
5
|
3
|
4
|
2
|
|
| Note Receivable |
0
|
1
|
1
|
0
|
2
|
1
|
1
|
0
|
|
| Other Long-Term Assets |
5
|
69
|
6
|
13
|
22
|
67
|
157
|
182
|
|
| Total Assets |
239
N/A
|
429
+80%
|
293
-32%
|
722
+147%
|
1 120
+55%
|
1 331
+19%
|
1 849
+39%
|
1 670
-10%
|
|
| Liabilities | |||||||||
| Accounts Payable |
4
|
8
|
81
|
5
|
7
|
33
|
153
|
205
|
|
| Accrued Liabilities |
8
|
34
|
0
|
71
|
101
|
149
|
102
|
60
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
1
|
2
|
1
|
4
|
3
|
5
|
|
| Other Current Liabilities |
40
|
117
|
13
|
38
|
121
|
112
|
91
|
175
|
|
| Total Current Liabilities |
52
|
159
|
94
|
116
|
229
|
298
|
216
|
278
|
|
| Long-Term Debt |
0
|
4
|
5
|
2
|
122
|
281
|
325
|
346
|
|
| Deferred Income Tax |
0
|
0
|
42
|
4
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
174
|
257
|
0
|
3
|
2
|
8
|
55
|
6
|
|
| Total Liabilities |
227
N/A
|
420
+86%
|
141
-66%
|
124
-12%
|
354
+184%
|
587
+66%
|
597
+2%
|
630
+5%
|
|
| Equity | |||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
12
|
9
|
151
|
598
|
766
|
744
|
1 251
|
1 041
|
|
| Total Equity |
12
N/A
|
9
-30%
|
151
+1 659%
|
598
+295%
|
766
+28%
|
744
-3%
|
1 251
+68%
|
1 041
-17%
|
|
| Total Liabilities & Equity |
239
N/A
|
429
+80%
|
293
-32%
|
722
+147%
|
1 120
+55%
|
1 331
+19%
|
1 849
+39%
|
1 670
-10%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
259
|
259
|
0
|
0
|
0
|
330
|
364
|
367
|
|
Switch to:
Switch to:
See Also
Discover More
